X hits on this document





18 / 49



November 9, 2010

  • 89.

    Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–1353.

  • 90.

    Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dys- function during intensive therapy for advanced chronic heart failure. Am Heart J. 1999;138(pt 1):285–290.

  • 91.

    Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311–1315.

  • 92.

    Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, van Veldhuisen DJ, Hillege HL. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007;13:599–608.

  • 93.

    Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, Horwitz RI. Correlates and impact on outcomes of worsening renal function in patients or 65 years of age with heart failure. Am J Cardiol. 2000;85:1110–1113.

  • 94.

    Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, Krumholz HM. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003;9:13–25.

  • 95.

    Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009; 360:1418 –1428.

  • 96.

    Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96:11G–17G.

  • 97.

    Gheorghiade M, Mebazaa A. Introduction to acute heart failure syn- dromes. Am J Cardiol. 2005;96:1G–4G.

  • 98.

    Cotter G, Moshkovitz Y, Milovanov O, Salah A, Blatt A, Krakover R, Vered Z, Kaluski E. Acute heart failure: a novel approach to its patho- genesis and treatment. Eur J Heart Fail. 2002;4:227–234.

  • 99.

    Graff L, Orledge J, Radford MJ, Wang Y, Petrillo M, Maag R. Corre- lation of the Agency for Health Care Policy and Research congestive heart failure admission guideline with mortality: peer review organi- zation voluntary hospital association initiative to decrease events (PROVIDE) for congestive heart failure. Ann Emerg Med. 1999;34(pt

    • 1)

      :429 – 437.

  • 100.

    Smith WR, Poses RM, McClish DK, Huber EC, Clemo FL, Alexander D, Schmitt BP. Prognostic judgments and triage decisions for patients with acute congestive heart failure. Chest. 2002;121:1610–1617.

  • 101.

    Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O’Connor CM, She L, Yancy CW, Young J, Fonarow GC; OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28:980–988.

  • 102.

    Ambardekar AV, Fonarow GC, Hernandez AF, Pan W, Yancy CW, Krantz MJ; Get With the Guidelines Steering Committee and Hospitals. Characteristics and in-hospital outcomes for nonadherent patients with heart failure: findings from Get With The Guidelines-Heart Failure (GWTG-HF). Am Heart J. 2009;158:644–652.

  • 103.

    Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005; 293:572–580.

  • 104.

    Filippatos G, Rossi J, Lloyd-Jones DM, Stough WG, Ouyang J, Shin DD, O’Connor C, Adams KF, Orlandi C, Gheorghiade M. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J Card Fail. 2007;13:360–364.

  • 105.

    Formiga F, Chivite D, Manito N, Casas S, Riera A, Pujol R. Predictors of in-hospital mortality present at admission among patients hospitalised because of decompensated heart failure. Cardiology. 2007;108:73–78.

  • 106.

    Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med. 1996;156:1814–1820.

  • 107.

    Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581–2587.

Downloaded from http://circ.ahajournals

  • 108.

    Auble TE, Hsieh M, Gardner W, Cooper GF, Stone RA, McCausland JB, Yealy DM. A prediction rule to identify low-risk patients with heart failure. Acad Emerg Med. 2005;12:514–521.

  • 109.

    Hsieh M, Auble TE, Yealy DM. Validation of the Acute Heart Failure Index. Ann Emerg Med. 2008;51:37–44.

  • 110.

    Silvers SM, Howell JM, Kosowsky JM, Rokos IC, Jagoda AS. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syn- dromes. Ann Emerg Med. 2007;49:627–669.

  • 111.

    Storrow AB, Collins SP, Lyons MS, Wagoner LE, Gibler WB, Lindsell CJ. Emergency department observation of heart failure: preliminary analysis of safety and cost. Congest Heart Fail. 2005;11:68–72.

  • 112.

    Peacock WF IV, Albert NM. Observation unit management of heart failure. Emerg Med Clin North Am. 2001;19:209–232.

  • 113.

    Peacock WF IV, Remer EE, Aponte J, Moffa DA, Emerman CE, Albert NM. Effective observation unit treatment of decompensated heart failure. Congest Heart Fail. 2002;8:68–73.

  • 114.

    Collins S, Schauer D, Gupta A, Brunner H, Storrow A, Eckman M. Cost-effectiveness analysis of ED decision making in non-high-risk heart failure patients. Am J Emerg Med. 2009;27:293–302.

  • 115.

    Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 1992;327:685–691.

  • 116.

    Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327: 669 – 677.

  • 117.

    Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–2199.

  • 118.

    Binanay C, Califf RM, Hasselblad V, O’Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW; ESCAPE Inves- tigators and ESCAPE Study Coordinators. Evaluation study of con- gestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294:1625–1633.

  • 119.

    Bourge RC, Abraham WT, Adamson PB, Aaron MF, Aranda JM Jr, Magalski A, Zile MR, Smith AL, Smart FW, O’Shaughnessy MA, Jessup ML, Sparks B, Naftel DL, Stevenson LW; COMPASS-HF Study Group. Randomized controlled trial of an implantable continuous he- modynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol. 2008;51:1073–1079.

  • 120.

    Drazner MH, Hellkamp AS, Leier CV, Shah MR, Miller LW, Russell SD, Young JB, Califf RM, Nohria A, Drazner MH, Hellkamp AS, Leier CV, Shah MR, Miller LW, Russell SD, Young JB, Califf RM, Nohria A. Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial. Circ Heart Fail. 2008;1:170–177.

  • 121.

    Mullens W, Borowski AG, Curtin RJ, Thomas JD, Tang WH, Mullens W, Borowski AG, Curtin RJ, Thomas JD. Tissue Doppler imaging in the estimation of intracardiac filling pressure in decompensated patients with advanced systolic heart failure. Circulation. 2009;119:62–70.

  • 122.

    Packer M, Abraham WT, Mehra MR, Yancy CW, Lawless CE, Mitchell JE, Smart FW, Bijou R, O’Connor CM, Massie BM, Pina IL, Greenberg BH, Young JB, Fishbein DP, Hauptman PJ, Bourge RC, Strobeck JE, Murali S, Schocken D, Teerlink JR, Levy WC, Trupp RJ, Silver MA; Prospective Evaluation and Identification of Cardiac Decompensation by ICG Test (PREDICT) Study Investigators and Coordinators. Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure. J Am Coll Cardiol. 2006;47:2245–2252.

  • 123.

    Shah MR, Hasselblad V, Stevenson LW, Binanay C, O’Connor CM, Sopko G, Califf RM, Shah MR, Hasselblad V, Stevenson LW, Binanay C, O’Connor CM, Sopko G, Califf RM. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA. 2005;294:1664–1670.

  • 124.

    Costanzo MR, Johannes RS, Pine M, Gupta V, Saltzberg M, Hay J, Yancy CW, Fonarow GC. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized

.org/ by guest on February 5, 2015

Document info
Document views205
Page views205
Page last viewedMon Jan 23 19:40:21 UTC 2017